Photo from wikipedia
Macrophage activation syndrome (MAS), a severe complication of systemic adult‐onset Still’s disease (AOSD), has been reported to occur during interleukin‐6 (IL‐6) inhibitor treatment. However, predictors for MAS development are unknown.… Click to show full abstract
Macrophage activation syndrome (MAS), a severe complication of systemic adult‐onset Still’s disease (AOSD), has been reported to occur during interleukin‐6 (IL‐6) inhibitor treatment. However, predictors for MAS development are unknown. Therefore, this study investigated predictive features for MAS development after starting IL‐6 inhibitor treatment in systemic AOSD patients.
Keywords:
macrophage activation;
inhibitor treatment;
activation syndrome;
inhibitor;
systemic adult
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!